BioCote Company Size, Employees, Growth and Industry: Inside the Specialist Antimicrobial Business Behind Global Product Protection

BioCote appears across healthcare, plastics, coatings, textiles, food-contact materials and other manufacturing sectors, yet it is not a large biotechnology corporation with hundreds or thousands of employees. The Coventry-based company operates as a highly specialised antimicrobial additive supplier whose commercial model depends heavily on technical expertise, manufacturing partnerships and technology integration.

That distinction matters for anyone researching BioCote company size, employees, growth and industry. A broad LinkedIn classification places BioCote in the 11–50 employee bracket, while financial-data services extracting figures from its latest UK filings report an average workforce of 14 employees for the financial year ending 31 October 2025, compared with 15 the previous year.

The business is also older than its legal incorporation date may initially suggest. BioCote says its commercial history began in 1994, while BioCote Limited, company number 03460699, was incorporated in England on 5 November 1997 and remains active.

Bottom line: BioCote is a privately held UK antimicrobial technology company with a specialist workforce of roughly 14 employees according to the latest available filing-derived data. Its growth story is based less on rapid headcount expansion and more on antimicrobial product integration, international partnerships, technical expertise and long-term participation in specialist manufacturing markets.

Where BioCote Fits in the Antimicrobial Technology Industry

BioCote’s central business is antimicrobial additives.

These additives are introduced during manufacturing to give materials properties that inhibit or reduce microbial growth. BioCote says its technology is used with plastics and polymers, paints and coatings, textiles and fabrics, as well as other specialist materials.

Common active technologies used by the company include silver ion, zinc and copper-based systems, alongside certain organic antimicrobial technologies.

Its addressable industries therefore extend considerably beyond what the word “biotechnology” might imply.

Healthcare and medical products

Healthcare is one of the clearest applications. BioCote describes antimicrobial additives being incorporated into products including medical equipment, breathing-related products, patient beds, stretchers, wall cladding and other frequently touched surfaces.

Plastics and polymer manufacturing

Antimicrobial masterbatches, powders and related formulations can be added during moulding or extrusion. BioCote identifies plastics and polymers as one of its major material categories and lists manufacturers using antimicrobial functionality in consumer, healthcare and industrial applications.

Paints, coatings and surface materials

BioCote also supplies additives intended for incorporation into liquid, powder and other coating systems. This creates exposure to construction, interiors, industrial surfaces, healthcare environments and specialist product manufacturing.

Food-contact environments

BioCote promotes HACCP International certification as an important part of its position in applications involving food-contact surfaces. Its website describes the certification as allowing its technology to be incorporated into appropriate materials used in food-related environments.

This broad material compatibility is a major reason BioCote can participate in multiple industries despite its comparatively small workforce.

Growth Has Come in Waves, Not Through Continuous Headcount Expansion

BioCote has publicly documented several periods of business expansion.

One significant phase came around 2019, when HACCP International reported that BioCote had invested more than £600,000 in larger headquarters and new laboratory facilities in Coventry. The report also stated that revenue had risen by 15% over the preceding year, accompanied by rising customer numbers and additional staff.

Another acceleration occurred around 2020–2021. BioCote reported strong demand for antimicrobial coatings and said it had doubled production capacity for liquid additives used in coatings. Managing Director David Hall linked the development to increased demand for products incorporating antimicrobial technology.

These historical expansion periods are important, but they should not be confused with evidence that BioCote is currently growing at the same rate.

These figures indicate a year-on-year reduction in several balance-sheet measures rather than obvious short-term expansion. They do not, however, establish whether revenue or operating profit rose or fell because turnover and profit are not displayed in the cited filing-data summary.

That makes claims such as “BioCote revenue is rapidly growing in 2026” impossible to verify responsibly from the available public accounts.

Commercial databases publish their own estimated revenue figures, but those estimates vary and should not be treated as audited or company-confirmed revenue.

From 1994 to 2026: The Milestones That Explain BioCote’s Position

BioCote’s development can be viewed through several identifiable stages.

1994 — Commercial origins: BioCote states that its antimicrobial technology business dates back to 1994.

1997 — Legal incorporation: BioCote Limited was incorporated on 5 November 1997.

2019 — Facilities investment: The business reportedly invested more than £600,000 in expanded headquarters and laboratory capacity, while reporting 15% annual revenue growth at the time.

2020 — Management and growth planning: David Hall joined as managing director as BioCote discussed a new growth roadmap. Companies House records Hall becoming a director in July 2021.

2021 — Production capacity expansion: BioCote said demand had driven it to double liquid-additive production capacity for coatings.

2024 — 30-year anniversary: The company marked three decades of operations, highlighting expansion of its product offering and international industry collaborations.

2026 — Continued partner activity: BioCote’s current website continues to feature new technology applications and partner projects, including antimicrobial coatings and laminate applications.

The timeline points to a mature specialist business rather than an early-stage startup pursuing rapid employee growth.

Why a 14-Person Company Can Support Products Across Multiple Markets

BioCote’s relatively modest employee count is less surprising once its business model is considered.

The company does not need to manufacture every finished antimicrobial product carrying its technology. Instead, BioCote develops and supplies additives and helps manufacturers incorporate them into their own materials.

Its partnership programme describes support spanning antimicrobial additive supply, independent testing, integration guidance, regulatory considerations, technical expertise and marketing support.

That creates a form of operational leverage.

A specialist BioCote team can work with a manufacturer whose own factories, distribution network and customers are significantly larger. Once an antimicrobial formulation is incorporated into that manufacturer’s production process, the finished products can potentially reach multiple territories without BioCote building equivalent manufacturing infrastructure itself.

BioCote’s company size should therefore be read alongside the size of its partner ecosystem, not in isolation.

BioCote founder Rainer Clover said during the company’s 30th-anniversary coverage that the business intended to continue innovating and contributing to projects with companies worldwide.

BioCote’s Leadership Structure Remains Closely Held

Companies House currently identifies Rainer Clover, David Robert Hall and Gregory David Kenney as active directors, with Clover also serving as company secretary.

BioCote identifies Clover as its founder, while company material describes David Hall as managing director.

This relatively compact leadership structure is consistent with the company’s wider profile: specialised, privately held and technically focused rather than organised as a large publicly traded life-sciences corporation.

What BioCote’s Financial Scale Does — and Does Not — Tell Us

The latest filing-derived data reports approximately £3.04 million in total assets, £2.84 million in net assets and £1.45 million in cash at 31 October 2025.

Those figures offer useful insight into balance-sheet size but should not be confused with revenue, valuation or market capitalisation.

BioCote is privately held, so there is no continuously quoted public market valuation.

Similarly, third-party websites publishing estimated BioCote revenue or valuation numbers are using proprietary models rather than audited figures disclosed by the company. Those estimates can be useful for broad market research but should not be presented as confirmed financial facts.

The safest interpretation is that BioCote operates as a small specialist company with a multimillion-pound balance sheet and international commercial relationships.

The Real Scale of BioCote Is Better Measured by Reach Than Headcount

BioCote presents an unusual company-size profile.

Measured purely by employees, it is small: roughly 14 people according to the latest filing-derived figure. Measured by technical reach, however, the company operates across numerous manufacturing categories and has spent more than three decades building antimicrobial technologies intended for integration into products made by other businesses.

Its historical record shows periods of investment, capacity expansion and revenue growth, while the latest balance-sheet data points to a more restrained recent year rather than obvious rapid expansion.

That combination is the clearest way to understand BioCote company size, employees, growth and industry: it is a mature, privately held antimicrobial technology specialist whose influence depends on intellectual property, formulation expertise, testing, regulation and manufacturing partnerships far more than on maintaining a large payroll.

FAQs.

How many employees does BioCote have?

BioCote is a small specialist employer. LinkedIn places the company in the 11–50 employee category, while filing-derived financial data reports an average of 14 employees in the financial year ending 31 October 2025, compared with 15 in 2024.

Is BioCote a large company?

BioCote is not a large company by workforce size. It is a privately held specialist technology supplier headquartered in Coventry. Its reach is broader than its employee count because its antimicrobial additives are integrated by partner manufacturers into products used across several industries and international markets.

What industry is BioCote in?

BioCote operates in antimicrobial technology and specialty additives. LinkedIn categorises it under biotechnology, while Companies House records its SIC activity under professional, scientific and technical services. Its practical markets include plastics, coatings, textiles, healthcare, construction, food-related surfaces and consumer products.

Is BioCote growing?

BioCote has documented significant historical growth periods, including a 15% revenue increase around 2019 and production-capacity expansion during the pandemic-era increase in antimicrobial demand. The latest 2025 filing-derived data, however, shows slightly lower employees, assets, cash and net assets than 2024, so continuing rapid growth should not be assumed without updated revenue figures.

When was BioCote founded?

BioCote says its business history began in 1994, meaning it passed 30 years of antimicrobial-technology activity in 2024. The current legal entity, BioCote Limited, was incorporated in England on 5 November 1997. Both dates are relevant because one reflects the company’s commercial history and the other its formal corporate registration.

Where is BioCote based?

BioCote is headquartered at 3 Parade Court, Central Boulevard, Prologis Park, Coventry, CV6 4QL, United Kingdom. The address appears both on the company’s current website and its Companies House registration.

Editorial Disclaimer

BioCote is privately held and does not publish the same level of financial disclosure expected from a listed public company. Employee and balance-sheet figures in this article reflect the latest publicly available filing-derived information located during research. Revenue estimates, valuations and other figures published by commercial data providers should not be treated as audited BioCote financial disclosures unless independently confirmed.

Businessbiohub.com